Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer

Autores de IIS La Fe

• Antonio Conde Moreno

  Autor

Participantes ajenos a IIS La Fe

• Rodríguez Pérez, A.
• Felip, E.
• Chicas-Sett, R.
• Montero, Á.
• de Paz Arias, L.
• González-Del-Alba, A.
• Lopez-Campos, F.
• López-López, C.
• Hernando-Requejo, O.
• Arranz-Arija, J.Á.
• de Castro Carpeño, J.

Grupos

• Investigación Clínica y Traslacional en Cáncer

Abstract

Oligometastatic disease (OMD) defines a cancer status that is intermediate between localized and widely spread metastatic disease, and can be treated with curative intent. While diagnostic imaging tools have considerably improved in recent years, unidentified micrometastases can still evade current detection techniques, allowing the disease to progress. The various OMD scenarios are mainly defined by the number of metastases, the biological and molecular tumour profiles, and the timing of the development of metastases. Increasing knowledge has contributed to the earlier and improved detection of OMD, underlining the importance of early disease control. In view of increasing OMD detection rates in current real-world clinical practice and the lack of standardized evidence-based guidelines to treat this cancer status, a board of experts from the Spanish Societies of Radiation Oncology (SEOR) and Medical Oncology (SEOM) organized a series of sessions to update the current state-of-the-art on OMD from a multidisciplinary perspective, and to discuss how results from clinical studies might translate into promising treatment options. This expert review series summarizes what is known and what it is pending clarification in the context of OMD in the scenarios of non-small cell lung cancer and breast cancer (Part I), and prostate cancer and colorectal cancer (Part II), aiming to offer specialists a pragmatic framework to help improve patient management. © 2022, The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Keywords

• immune checkpoint inhibitor; protein tyrosine kinase inhibitor; sorafenib; ablation therapy; abscopal effect; antineoplastic activity; Article; brain metastasis; breast cancer; cancer prognosis; clinical practice; colorectal cancer; decision making; disease control; drug efficacy; fractionation; histopathology; hormonal therapy; human; human tissue; immunotherapy; liver metastasis; mediastinum lymph node; melanoma; metastasis; metastatic breast cancer; micrometastasis; minimal residual disease; molecularly targeted therapy; morbidity; mortality; non small cell lung cancer; oligometastatic disease; oncology; positron emission tomography-computed tomography; prostate cancer; radiation; radiation dose; radiofrequency ablation; systemic therapy; triple negative breast cancer; tumor volume; breast tumor; lung tumor; male; pathology; procedures; prostate tumor; radiosurgery; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Medical Oncology; Prostatic Neoplasms;